

B' Cond.
(a) anti-very late antigen-4 (VLA-4) antibody which may optionally be human, chimeric or humanized, and Fab, Fab', F(ab')₂ or F(v) fragments thereof;

(b) fibronectin, fibronectin having an alternatively spliced non-type III connecting segment, fibronectin peptides containing the amino acid sequence EILDV or a similar conservatively substituted amino acid sequence; and

(c) soluble vascular cell adhesion molecule-1 (VCAM-1) and VCAM-1 peptides.

B²
7. (Amended) The method according to claim 4, wherein the stimulation is mediated by a cytokine selected from the group consisting of: granulocyte colony stimulating factor (G-CSF), stem cell factor (SCF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and interleukins 1, 2, 3, 4, 6 and 11 (IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11).

8. (Amended) The method according to claim 5, wherein the stimulation is mediated by a cytokine selected from the group consisting of: granulocyte colony stimulating factor (G-CSF), stem cell factor (SCF), granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage colony stimulating factor (M-CSF), and interleukins 1, 2, 3, 4, 6 and 11 (IL-1, IL-2, IL-3, IL-4, IL-6 and IL-11).

B³
10. (Amended) The method according to claim 7, wherein the cytokine is granulocyte colony stimulating factor (G-CSF).